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ABSTRACT 
 
Nuchal Translucency as a method of First Trimester Screening for Aneuploidy in a 
South African population 
 
Background  
Chromosomal abnormalities constitute 15% of congenital abnormalities and 50% of 
pregnancy losses. Twenty-five percent of these will be Trisomy 21.  Down’s syndrome has a 
birth incidence of 2 per 1000 and constitutes 25% of severe mental handicap in the developed 
world. Whereas the risk assessment focuses on Trisomy 21, the fetuses that screen positive are 
also known to contain other defects, which include anomalies such as cardiac defects, 
diaphragmatic hernias, neuromuscular disorders, and rare genetic syndromes.  
Objective 
To determine the effectiveness of nuchal translucency (NT) screening in predicting aneuploidy 
and structural abnormalities in a South African population 
Setting  
Chris Hani Baragwanath Hospital Fetal Medicine Unit 
Study design  
Descriptive Study 
Methodology  
The Fetal Medicine Unit database was reviewed and the records of patients who had 
undergone NT screening between July 2003 and July 2005 were retrieved.  There were no 
exclusions. An adjusted risk was derived from the combination of age-related risk and the risk 
derived from nuchal translucency screening. A positive screen was denoted by an adjusted risk 
of more than 1/300 and a negative screen was denoted by an adjusted risk of less than 1/300.  
Results 
A total of 428 patients had first trimester screening during this period. Thirteen patients (3%) 
were lost to follow up. Of the 415 cases that were analyzed, 57 patients screened positive and 
356 patients screened negative. In addition, 2 fetuses with acrania were detected. The mean 
age for both groups of patients was 30.1 years. The crown-rump length of fetuses with a 
positive screen was statistically significantly shorter than fetuses that screened negative. Of 
the 57 patients that screened positive 24 elected to have chorionic villus sampling (CVS) 
which resulted in the detection of 6 chromosomal abnormalities and 2 structural abnormalities. 
Of the remaining 356 patients, who had screened negative, 2 had an increased adjusted risk, 
and one chromosomal abnormality was detected in this group.  
Of the remaining 354 patients, 8 elected to have CVS because of a previous history of 
chromosomal abnormality. All of them proved to be normal. 
Conclusions  
The use of such screening has enabled prenatal karyotyping to be focused on pregnancies at 
highest risk for chromosomal abnormalities regardless of age. 
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1. INTRODUCTION 
1.1 BACKGROUND 
The use of first trimester screening to detect chromosomal and structural abnormalities is well 
established.1,2,3 The first trimester screening programme which incorporates maternal age 
derived background risk, nuchal translucency measurement, the presence of a nasal bone, and 
biochemical screening, was designed by the Fetal Medicine Foundation in London. It is used 
in many institutions in South Africa. However, data on its use in a predominantly black South 
African population is limited.  
 
The ethnic diversity of the South African population, as well as the financial constraints, limits 
the scope of health practice.  Health care costs have risen above inflation over the last decade, 
with only marginal increments in the health budget, and as a result many first trimester 
screening centers in Gauteng have been forced to omit biochemical screening.  
 
This study is an attempt to evaluate the use of a first trimester screening programme, without 
biochemical screening, in a predominantly black population. 
 
1.1.1 THE BURDEN OF CONGENITAL DISORDERS 
For the purpose of this study the definition of a congenital abnormality, will be that employed 
by Christianson, et al4, which refers to conditions of prenatal origin, with structural defects, 
functional abnormalities, inborn errors of metabolism and chromosomal aberrations.  
Congenital anomalies in rural black South African neonates occur in 15.23 per 1000 live 
births5. It has been estimated that the cumulative incidence by age 5 years of serious genetic 
disorders and birth defects may affect 5-8% of all babies born each year6.  
  
In a study of rural black South African neonates, malformations of the central nervous system 
were those noted most frequently, with an incidence of 4.33 per 1000 births, followed by 
musculoskeletal abnormalities and chromosomal defects5. In this study, chromosomal 
disorders were found to have an incidence of 2.75 per 1000 live births.  Down’s syndrome, 
which has a worldwide incidence of 1 in 700 births, for singleton pregnancies7, was found in 
2.1 per 1000 live births among black neonates in rural areas5. 
 
TABLE 1.1 BIRTH PREVALENCE AND OUTCOMES OF BIRTH DEFECTS IN 
POPULATIONS OF NORTH EUROPEAN ORIGIN. (Adapted from Christianson, et 
al8) 
Group of Conditions Birth    prevalence 
 /1000 
Early 
Mortality 
/1000 
Chronic 
problems 
/1000 
Cure  
/1000 
Congenital malformations 36.5 8 8.8 19.7 
Chromosomal disorders 3.8 1.3 2.4 0.1 
Single gene disorders 12.3 7.1 3.8 1.4 
 
The figures quoted in Table 1.1 show that congenital abnormalities, including chromosomal 
defects, have a higher prevalence in the Northern European populations when compared to 
third world countries, such as rural South Africa.   This may be related to better postpartum 
detection facilities. 
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Assisted reproductive techniques also increase the burden of prenatal diagnostics. In first 
world countries, twin pregnancies also account for 1.3 per 100 births and this rate is 
increasing, due to the use of assisted reproductive technology.9 
 
The outcome of infants born with congenital abnormalities depends on the severity of the 
congenital disorder, as well as the level of development of health services. In low-resource 
settings most affected infants die undiagnosed, but as services become available an increasing 
proportion are cured, or survive with chronic disabilities such as Down’s syndrome, neural 
tube defects, or mental retardation.10  It was estimated in 1983 that R 1 billion was spent on 
the management of congenital or genetic conditions. Inflation, increase in population, better 
adult education, and improved survival, have led to a quadrupling of the cost incurred.5  
 
It is the parents of congenitally abnormal children who bear the greatest burden.  
Caring for a congenitally abnormal or mentally retarded child is expensive and emotionally 
traumatic to both parents. Chromosomal abnormalities such as Down’s syndrome may prove 
to be a greater burden than those with lethal abnormalities, since many of these children reach 
adulthood and are unable to support themselves.  They will then become a social and financial 
burden for close relatives.  
 
1.1.2 CALCULATION OF RISK FOR CHROMOSOMAL DISORDER 
A woman’s risk of having a congenitally abnormal baby is determined by her a priori risk, 
which in turn is dependant upon: maternal age, the duration of the pregnancy and a history of 
previous congenital abnormalities. Every time a test is performed, this background risk is 
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multiplied by the test factor or likelihood ratio, from which a new risk is then derived, and this 
becomes the a priori risk for the next test.7 This pattern of screening is referred to as 
sequential screening. The components of sequential screening are: maternal age; biochemistry 
screening; nuchal translucency screening; ductus venosus flow; and the presence of the nasal 
bone. 
 
1.1.2.1 MATERNAL AGE AND GESTATIONAL AGE 
It is well established that the incidence of chromosomal abnormalities increases 
proportionately with an increase in the maternal age.7,11,12,13  The evidence to support maternal 
age related risk of Trisomy 21 comes from a Survey in the South of Belgium14 where each 
neonate was examined for Trisomy 21, and in a Swedish survey15 where information was 
confirmed using birth records and other resources. The latter 2 surveys established, without a 
doubt, the proportionate risk between advanced maternal age and the incidence of Trisomy 21. 
Figure 1-17 reflects that Trisomy 21 is noted with a greater frequency than Trisomies 18 and 
13 respectively, in association with advancing maternal age. The risk of Turner’s syndrome 
and Triploidy remains constant with age (Figure 1-1).  
 
Fetuses with chromosomal abnormalities are more likely to die in utero than normal fetuses 
and hence the risk decreases with advancing gestation (Figure 1-2).7 To calculate the relative 
risk of Trisomy 21 at different gestations, Snijders, et al13, used data from 57 614 women who 
had fetal karyotyping at 9-16 weeks gestation for the sole indication of maternal age of 35 
years or more.13 They then calculated the expected number of Trisomy 21 cases for each 
gestational age subgroup, by comparing the maternal age distribution and the maternal age 
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related risk for Trisomy 21. The derived prevalence of Trisomy 21 by maternal age and 
gestational age is reflected in Table 1.2. 
 
Figure 1-1 MATERNAL AGE-RELATED RISK FOR CHROMOSOMAL 
ABNORMALITIES7 
   
(The lines represent the relative risk according to the risk at 10 weeks of gestation) 
Figure 1-2 GESTATIONAL AGE-RELATED RISK FOR 
CHROMOSOMAL ABNORMALITIES7 
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Table 1.2 PREVALENCE OF TRISOMY 21 BY MATERNAL AGE AND 
GESTATIONAL AGE. (Adapted from Snijders, et al13) 
Gestational age (weeks) Maternal 
age (years) 10 12 14 16 20 40 
20 1/983 1/1068 1/1140 1/1200 1/1295 1/1527 
25 1/870 
 
1/946 
 
1/1009 1/1062 1/1147 1/1352 
30 1/576 
 
1/626 1/668 1/703 1/759 1/895 
34 1/287 
 
1/312 1/333 1/350 1/378 1/446 
35 1/229 
 
1/249 1/266 1/280 1/302 1/356 
36 1/180 
 
1/196 1/209 1/220 1/238 1/280 
37 1/140 
 
1/152 1/163 1/171 1/185 1/218 
38 1/108 
 
1/117 1/125 1/131 1/142 1/167 
39 1/82 
 
1/89 1/95 1/100 1/108 1/128 
40 1/62 
 
1/68 1/72 1/76 1/82 1/97 
 
 
 1.1.2.2 PREVIOUS CHROMOSOMAL ABNORMALITIES 
Nicolaides, et al stated that in a study of 2054 women who had a previous pregnancy with 
Trisomy 21, it was found that the risk of recurrence in the subsequent pregnancy was 0.75% 
higher than the maternal and gestational age-related risk for Trisomy 21 at the time of testing.7 
Similar recurrence rates have been quoted for Trisomy18.7,16 Hence, this influences the a  
priori risk by a factor of 0.75.7 
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1.1.3 NUCHAL TRANSLUCENCY 
1.1.3.1 HISTORICAL ASPECTS 
In a paper published by Langden Down: “Observations of an ethnic classification of the 
idiots”, he described the skin of babies with Trisomy 21 as being deficient in elasticity and 
giving the appearance of being too large for the body.17 
 
Langden Down was the first to describe the phenotypic appearance of Trisomy 21 babies and 
hence the appellation Down’s syndrome, which is used interchangeably with the term Trisomy 
21.  
 
In 1959 Lejeune, et al were the first scientists to attribute a congenital birth defect to a 
chromosomal abnormality (Trisomy 21).18  
 
Down’s description of the appearance of the skin of babies with Trisomy 21, was the basis for 
the ultrasonographic observation, made more than a century later, by Sazbo and Gellen19, 
where nuchal fluid accumulation in Trisomy 21 fetuses were first detected via transvaginal 
ultrasonography. Over a period of 3 years, Sazbo and Gellen19, examined 7 fetuses with 
Trisomy 21 and confirmed these findings in all of them. The typical ultrasonographic 
appearance of accumulation of nuchal subcutaneous fluid can be seen in Figure 1-3. 
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FIGURE 1-3 ULTRASOUND PICTURE OF A 12 WEEK FETUS WITH TRISOMY 21. 
(Distance between calipers demonstrates increased nuchal translucency thickness.) 
Image kindly provided by Prof Ermos Nicolaou, University of the Witwatersrand. 
 
 
1.1.3.2 NUCHAL TRANSLUCENCY OR CYSTIC HYGROMA? 
In 1994, Trauffer, et al20, stated that a nuchal cystic hygroma found during second trimester 
ultrasound scan, has a strong association with aneuploidy, most commonly 45 X, but also 
Trisomies 21 and 18. Trauffer, et al further stated that when the Karyotype was normal, the 
cystic hygroma may signal the presence of a single gene defect such as Noonan syndrome. For 
many years this appearance of subcutaneous thickening of the skin behind the neck, was 
referred to as a cystic hygroma. In the second trimester the association between subcutaneous 
skin thickening and aneuploidy is recognized. However, the term nuchal translucency arose as 
a delineation of the first trimester nuchal fluid accumulation from the second trimester skin 
thickening.  
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1.1.3.3 FETAL NUCHAL FLUID- PHYSIOLOGICAL OR PATHOLOGICAL? 
In 1976, Nishimura H and Okamoto N21, found that these subcutaneous fluid collections were 
present in 40% of embryos at less than 10 weeks, and had resolved a week later. Chervenak, et 
al22, stated that pathological fluid collections may occur when there is congenital dysplasia of 
the lymphatic system and failure of its connection with the internal jugular system.  
 
In 1990 lesions were considered to be pathological when they were greater than 5 mm in 
depth.23 Wilson, et al24, reported on the findings of 43 pregnancies, where the embryos or 
fetuses had increased nuchal fluid prior to 17 weeks. They concluded from their study that 
nuchal fluid may be physiological or pathological; however recognition of those patterns 
which are pathological is important to allow invasive prenatal assessment for chromosome 
evaluation while minimizing the risk of post-procedural spontaneous loss of chromosomally 
normal fetuses.24 
 
1.1.3.4 THE FETAL MEDICINE FOUNDATION PROJECT - NUCHAL 
TRANSLUCENCY AND ANEUPLOID FETUSES 
In August 1998, the publication by Snijders, et al1 reported on 100 311 singleton pregnancies 
with live fetuses, which were examined by means of ultrasonography at a median gestation of 
12 weeks. Ninety six thousand and one hundred and twenty seven fetuses had either prenatal 
or postnatal karyotyping performed, or were assessed by examination of the neonate for 
dysmorphic features.  
The findings of this UK Multicenter project changed the approach to prenatal screening for 
Trisomy 21 as well as for other abnormalities.  
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This multicentre project identified 326 fetuses with Trisomy 21 and 325 fetuses with other 
chromosomal abnormalities. Snijders, et al1 reported that the fetal nuchal translucency 
thickness was above the 95th percentile for nuchal translucency nomograms as derived from 
crown-rump length, in 4.4% of the 96 476 normal pregnancies. These authors found that the 
estimated risk of Trisomy 21, based on the maternal age and the fetal nuchal translucency 
thickness, was 1:300 or higher in 8.3% of normal pregnancies; 82.2% of those with Trisomy 
21; and 77.8% of those with other chromosomal defects.  
 
Therefore, for a cut-off estimated risk of Trisomy 21 of 1:300, the sensitivity was 82.2%, the 
false positive rate was 8.3%, the positive predictive value was 3.2% and the negative 
predictive value was 99.9%.1 When adjusted to achieve a 5% false positive rate, the sensitivity 
fell to 77%.1 The various aneuploidies which were detected are depicted in Table1.3. 
 
TABLE 1.3 NUMBER OF PREGNANCIES WITH NUCHAL TRANSLUCENCY 
THICKNESS ABOVE THE 95th CENTILE AND THE ESTIMATED RISK FOR 
TRISOMY 21 OF 1:300 OR GREATER.(Adapted from Snijders, et al1) 
 
Fetal karyotype Total Number with NT 
thickness  
> 95th percentile 
Number with 
estimated risk  
1:300 or more 
Normal 95476 4209 (4.4%) 7907 (8.3%) 
Trisomy 21 326 234 (71.8%) 268 (80.2%) 
Other chromosomal abnormalities 
Trisomy 18 119 89 (74.8%) 97 (81.5%) 
Trisomy 13 46 33 (72%) 37 (80%) 
Turner’s syndrome 54 47 (87%) 48 (89%) 
Triploidy 32 19 (59%) 20 (63%) 
Other* 74 41 (55%) 51 (69%) 
Total 96127 4767 (4.9%) 8428 (8.8%) 
NT= nuchal translucency.  
*Deletions, partial Trisomies, unbalance translocations, sex chromosome aneuploidies. 
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1.1.3.5 NUCHAL TRANSLUCENCY AND EUPLOID FETUSES 
Since the initiation of the UK multicentre project there have been several reports of defects 
and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness 
at 10-14 weeks gestation.25,26,27,28 Souka, et al25 reported on 4116 singleton, chromosomally 
normal pregnancies with fetal nuchal translucency thickness above the 95th percentile for 
crown rump length, at a median gestation of 12 weeks. They found an overall outcome of 
3885 live births of infants who survived the neonatal period, 38 neonatal deaths, 74 
spontaneous abortions or intra-uterine deaths and 77 terminations at the request of the parents 
because of fetal abnormalities detected by ultrasonography (Table 1.4).25 
 
Cardiac abnormalities are also common and although most of the ultrasonographic features 
may be detected by specialist fetal echocardiography at the18-22 week scan, many 
abnormalities are undetected at routine antenatal ultrasonography.28  
 
Data published by Zosmer, et al28, revealed that there is a high association between increased 
nuchal translucency and major cardiac defects. They stated that where the nuchal translucency 
measurement was greater than 3.5mm, the prevalence of cardiac defects was increased tenfold.  
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TABLE 1.4 FETAL ABNORMALITIES AND GENETIC SYNDROMES IN 
CHROMOSOMALLY NORMAL FETUSES WITH INCREASED NUCHAL 
TRANSLUCENCY THICKNESS AT 10-14 WEEKS GESTATION ACCORDING TO 
NUCHAL TRANSLUCENCY THICKNESS (mm) (Adapted from Souka, et al25) 
Fetal nuchal translucency thickness (mm) Pregnancy outcome Fetal abnormality 
<3.5 3.5-4.4 4.5-5.4 5.5-6.4 ≥6.5 TOP IUD NND Alive 
Anencephaly 4 1    5    
Encephalocoele 3    1 4    
Ventriculomegaly 6     5   1 
Dandy Walker cyst 1     1    
Holoprosencephaly 1     1    
Microcephaly 1        1 
Facial cleft 2        2 
Cystic hygroma 1        1 
Major cardiac defects 12 12 6 3 10 19 6 3 15 
Diaphragmatic hernia 4 1 3 1  1  5 2 
Exomphalos 2 3 1 1  5 1  1 
Gastroschisis  1      1  
Bowel obstruction 2        2 
Duodenal atresia  1       1 
Hydronephrosis 2 2 1   1   4 
Multicysic kidneys 4     3   1 
Polycystic kidneys     1 1    
Renal agenesis 1 1    1   1 
Megacystis 7 1    2 2  4 
Spina bifida 3 1    2 1  1 
Kyphoscoliosis    1  1    
Diastomatomelia 1        1 
Talipes 10 4 1   1   14 
TOP=Termination of pregnancy 
IUD=Intrauterine death 
NND=Neonatal Death 
 
However, because of technical limitations and uncertainty concerning pathophysiology of 
congenital cardiac abnormalities, Zosmer, et al28 regard a second follow up scan at 20 weeks, 
as necessary in cases with apparently normal echocardiography at 14-16 weeks. 
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1.1.3.6 THE OPTIMAL GESTATIONAL AGE TO EXAMINE FETAL NUCHAL 
TRANSLUCENCY  
In both normal and abnormal fetuses, the nuchal translucency measurements increase 
significantly with increasing gestation.29 Braithwaite, et al29, demonstrated that an increase in 
the mean crown rump length measurements from 44.8mm to 70.1 mm resulted in a mean 
increase in the nuchal translucency of 0.66 mm. Hence a single cut off value becomes 
inappropriate. There is a need for consistent results which are precise and repeatable for 
general population screening. Hence normograms for nuchal translucency were developed in 
relation to crown rump length measurements. 
 
It is best to review nuchal translucency at a crown rump length of between 45mm and 84mm 
or a gestation of 11 to 14 weeks.7 The reason for the upper cut off limit being set at 13 weeks 
and 6 days, is to allow women with abnormal fetuses the option of an earlier and safer 
termination of the pregnancy. 
 
1.1.4 SCREENING THE GENERAL POPULATION 
Roberts, et al30 stated that if nuchal translucency ≥ 3mm were used as an indicator for 
karyotyping, 6% of the normal pregnant population would screen positive, but the percentage 
would vary greatly depending on the gestational age profile of the screened population.  In an 
unselected population, the value of nuchal translucency measurement as a screening test for 
Down’s syndrome could be diminished. 
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1.1.5 THE ANATOMICAL SURVEY 
Braithwaite, et al31 examined 298 consecutive women attending a routine gestational-dating 
scan clinic at between 12 and 14 weeks’ gestation, and offered high resolution 
ultrasonographic examination of the fetus via the trans-abdominal and trans-vaginal approach. 
Complete surveys of fetal anatomy were possible in 72% of women with trans-abdominal 
sonar, 82% with trans-vaginal sonar and 95% by a combination of the 2 scan modes.31 
 
Thus, using the anatomical survey proposed by these workers, it is possible to perform a 
complete anatomical assessment in 95% of fetuses by combining the 2 scan modes at 12-13 
weeks of gestation.(Table 1.5) 
 
TABLE 1.5 CRITERIA NECESSARY FOR ADEQUATE VISUALIZATION OF 
FETAL ORGANS31 
 
Organ Criteria necessary for adequate visualization 
Head Complete cranium, septum pellucidum, thalamus, choroid plexi, 
cerebellum and ventricles 
Face Correct position of mandibles, maxillae and orbits 
Heart Four chamber view, symmetrical ventricles and atria 
Diaphragm Hypoechoeic interface between abdomen and thoracic cavities 
Stomach Single, hypoechoic structure in the left upper abdomen 
Abdominal wall Normal cord insertion and abdominal wall 
Kidneys Visualization of the cortex and pelvis of both kidneys 
Bladder Hypoechoic structure anteriorly in the midline of the pelvis 
Spine Complete vertebrae seen in both transverse and coronal planes with 
normal overlying skin 
Extremities Visualization of long bones, correct posture of hands and feet 
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1.1.6 BIOCHEMISTRY AND SEQUENTIAL SCREENING 
First trimester biochemistry screening employs the use of assays of serum pregnancy 
associated plasma protein A and free beta subunit of human chorionic gonadotrophin levels. 
This may detect 60% of Trisomy 21 fetuses at a screen positive rate of 5%.32 The additional 
cost implications according to the South African national health reference price list is R393.20 
per test. In order to achieve a sensitivity of 97%, one would have to incorporate biochemistry 
screening into each test performed.7 However, in an outcomes analysis of five prenatal 
screening strategies for Trisomy 21 in women younger than 35 years33, it was found that 
sequential screening was the most cost-effective screening strategy for Trisomy 21. 
 
1.1.7 DIAGNOSIS BY INVASIVE TESTING 
No screening test is effective unless a suitable diagnostic procedure is available to validate 
findings. It has been suggested that routinely offering invasive testing to women over the age 
of 35 without biochemical testing should be abandoned.34 Chorionic villus sampling is the 
invasive procedure of choice in determining the karyotype of a fetus that screens positive in 
the first trimester. The advantage of earlier diagnosis is that it reduces the psychological 
impact of termination of pregnancy in women with abnormal fetuses, since fetal movements 
have not yet been felt. Earlier diagnosis also lends itself to an earlier and safer form of 
termination of pregnancy as opposed to a second trimester termination. With increasing 
experience, the complication rate of CVS versus amniocentesis equalizes.35 
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1.1.7.1 MATERNAL ACCEPTANCE OF CHORIONIC VILLUS SAMPLING 
There are various reasons why women decline or accept invasive testing. These reasons range 
from understanding or not understanding the fetal condition to religious reasons. Some may 
find even a minimal risk of a fetal abnormality unacceptable. 
 
In a study by Chasen, et al36, on 4029 women, it was found that higher rates of nuchal 
translucency screening were associated with lower rates of chorionic villus sampling and it 
was deduced that first trimester screening may lead to reduced rates of invasive testing and 
fewer losses of normal pregnancies.  
 
1.1.8 IMPROVING THE SENSITIVITY OF FIRST TRIMESTER 
SCREENING 
Screening for Down’s syndrome continues to improve. Recent studies have shown that 
sonographic markers such as the absence of a nasal bone and abnormal ductus venosus flow 
can enhance the sensitivity of screening.37,38,39  
 
1.1.8.1 SONOGRAPHIC ASSESSMENT OF DUCTUS VENOSUS FLOW 
The Doppler gate is placed in the ductus venosus between the umbilical venous sinus and the 
inferior vena cava. In Figure 1-4, it will be seen that there is biphasic pulsatile flow with 
constant forward flow, and the troughs of flow during atrial contraction also demonstrate 
forward flow.40 Forward  biphasic pulsatile ductus venosus flow is normal, whilst reversed 
flow at the time of atrial contraction has been associated with aneuploidy and congenital heart 
defects.38 
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FIGURE 1.4 DUCTUS VENOSUS FLOW VELOCITY WAVEFORM IN A NORMAL 
13 WEEK FETUS. Image kindly provided by Prof Ermos Nicolaou, University of the  
Witwatersrand 
 
1.1.8.2 SONOGRAPHIC ASSESSMENT OF THE NASAL BONE 41 
A mid-sagittal view of the fetal profile is obtained with the ultrasound transducer being held 
parallel to the longitudinal axis of the nasal bone. The angle of insonation is crucial because 
the nasal bone will seldom be visible when the longitudinal axis of the bone is perpendicular 
to the ultrasound transducer. In the correct view, there are 3 distinct lines. 
 
The first 2 lines, which are proximal to the forehead, are horizontal and parallel to each other, 
resembling an ‘‘equal sign.’’ The top line represents the skin and the bottom line, which is 
thicker and more echogenic than the overlying skin, represents the nasal bone (Figure 1-5).  
A third line, which is almost in continuity with the skin but at a higher level, represents the tip 
of the nose.  
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When the nasal bone line appears as a thin line, less echogenic than the overlying skin, it 
suggests that the nasal bone is not yet ossified and is classified therefore as being absent 
(Figure 1-6). 
 
FIGURE 1-5 NASAL BONE IN A CHROMOSOMALLY NORMAL FETUS AT 12 
WEEKS. Image kindly provided by Prof Ermos Nicolaou, University of the  
Witwatersrand 
 
 
 
 
FIGURE 1-6 ABSENT NASAL BONE IN A TRISOMY 21 FETUS AT 12 WEEKS. 
Image kindly provided by Prof Ermos Nicolaou, University of the Witwatersrand 
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Including sonographic screening for the nasal bone and tricuspid regurgitation into the first 
trimester screening programme would, for a fixed false-positive rate of about 5%, increase the 
detection rates from about 75% and to 97%.42 
 
1.1.9 MULTIPLE PREGNANCIES 
1.1.9.1 TYPES OF MULTIPLE PREGNANCIES 
Multiple pregnancies usually result from either fertilization of multiple ova or from splitting of 
one embryonic mass. The former is termed polyzygotic multiple pregnancies and the latter, 
monozygotic twinning.  In polyzygotic pregnancies each fetus has a separate placenta while in 
monozygotic pregnancies, the placenta is often shared. The incidence of twin pregnancies is 
2% of all pregnancies, with 2/3 being dizygotic and 1/3 being monozygotic. The incidence of 
monozygotic twins is constant and does not vary with age, parity and race but is increased 
following in vitro fertilization. The incidence of dizygotic twin pregnancies, on the other hand, 
is influenced by age, race and parity.  
 
1.1.9.2 SCREENING FOR ANEUPLOIDY IN TWIN PREGNANCIES 
Screening for aneuploidy in twins presents a complex array of problems since one has to 
determine if aneuploidy is present and, in particular, which fetus is affected. If a fetus is 
affected, then even further care needs to be taken to ensure that should a fetocide be required, 
that the correct fetus is terminated.  
The prenatal risk assessment for twin pregnancies is more complex than for singleton 
pregnancies. Prior to the advent of first trimester nuchal translucency screening, the only 
parameter available for risk screening was age. Biochemical screening using multiples of 
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median, currently has no place in twin pregnancies since the normograms extrapolated from 
singleton pregnancies are affected by the zygosity of the twin pregnancy.9 With technological 
advances in the field of infertility and in-vitro-fertilization, the incidence of multiple 
pregnancies continues to rise.  
 
In a study by Sebire, et al43, it was found that the sensitivity of fetal nuchal translucency 
thickness in screening for Trisomy 21 among twin gestations was similar to that in singleton 
pregnancies.  Specificity was lower, because translucency was also increased in association 
with an early onset of twin-twin transfusion syndrome in chromosomally normal 
monochorionic twin pregnancies. 
 
Whilst first-trimester nuchal translucency screening provides fetus-specific risk estimates, a 
positive screening test presents a dilemma regarding the decision as to which fetus is 
abnormal. To undertake an invasive diagnostic test would place both fetuses at risk.9 
 
Sebire, et al44 presented data on using the results of nuchal translucency as a guide to patients’ 
in their decision regarding having either a CVS in the first trimester or an amniocentesis in the 
second trimester. 
 
An added advantage of first trimester nuchal translucency screening in twin pregnancies, is the 
determination of chorionicity. 
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1.2 PURPOSE OF THE STUDY  
This study aims to assess a first trimester screening programme which incorporates maternal 
age derived background risk, nuchal translucency measurement, and the presence of a nasal 
bone in a tertiary care institution. Following the literature review, it is evident that advances in 
first trimester screening have improved the sensitivity of screening. However, there is limited 
data on its use in a predominantly black South African population. Expense, unlike in first 
world practice, is the most important limitation in South Africa.  
 
This study evaluates the quality of care provided with the use of a first trimester screening 
programme without biochemical screening, in a population that is primarily black. 
 
1.3 SETTING 
The Chris Hani Baragwanath Hospital is both a secondary and tertiary referral centre, that 
serves predominantly the surrounding health care clinics, and primary and secondary hospitals 
in the south of Johannesburg. More distant hospitals may refer patients for specialist opinion 
and management.  The domain of referral includes the entire Sowetan district which comprises 
a predominantly black population together with a few people of mixed ethnicity.  
 
Being a tertiary care institution, most patients are referred to the Chris Hani Baragwanath 
hospital complex, for attention to medical conditions that cannot be addressed at primary or 
secondary care level. Not all the health care clinics however have antenatal facilities, and 
hence approximately 30% of women attended to in the antenatal clinic attend of their own 
volition.  
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 Even in this low socio-economic community patients, including those referred from primary 
and secondary care facilities, may need to provide their own means of transport to health care 
facilities. State provided transport is only available to patients with acute medical conditions. 
Although it is difficult to commute, many patients seem to be willing to travel the distance 
because of the perception of being cared for in a “bigger and better” hospital.  
 
Referred patients are received and reviewed in the antenatal clinic at the Chris Hani 
Baragwanath Hospital, where they are interviewed and examined by doctors. After initial 
evaluation of the patient’s condition, every patient is referred to the fetal medicine unit for a 
baseline sonographic evaluation of the fetus, unless the pregnancy is already assessed to be 
term. The policy of the fetal medicine unit is to offer every pregnant woman at least one 
ultrasound scan in pregnancy. 
 
At the Fetal Medicine Unit, level 3 sonographers perform the initial ultrasonographic 
assessment of fetuses. Thereafter, if a fetus is found to be less than 14 weeks gestation or 
84mm in crown rump length, the patient is referred to the first trimester screening clinic. 
On arrival at the first trimester screening clinic, each patient is counseled by trained genetic 
counselors about the use of first trimester nuchal translucency screening for congenital 
abnormalities, and the patients a priori risk. First trimester screening is then only undertaken 
after obtaining verbal informed consent of the patient. 
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After the nuchal translucency measurement has been performed, the data is entered into a 
software programme provided by the Fetal Medicine Foundation in London, and a new a 
priori risk or adjusted risk is determined.  
 
The patient is then informed of her risk.  The majority will be reassured by a reduction in risk 
and will then opt to forego invasive diagnostic testing, in favor of a 20 weeks ultrasound 
assessment to review the fetal anatomy for structural markers of aneuploidy. Although only 
patients with a risk of greater than 1:300 are classified as screen positive and are offered 
invasive diagnostic testing via chorionic villus sampling, strict measures are not adhered to 
and occasionally, patients that screen negative may insist on having invasive testing 
performed.  This occurs most frequently in the event of there having been an abnormality in a 
previous pregnancy. 
 
The patient is informed by the genetic counselors that, should the baby have any abnormalities 
after birth, they should return to see the genetic counselor at the pediatric clinic. Attached to 
every antenatal record card is a printed copy of the first trimester screen, so that the doctors 
caring for the patient at the time of delivery are aware of the findings. 
 
Despite the expense, the majority of these patients manage to find transport back to the 
hospital for a sonographic review at 20 weeks. 
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1.4 OBJECTIVES 
1. To determine the effectiveness of nuchal translucency screening in predicting 
aneuploidy in a South African population at a tertiary care institution.  
2. To determine the types of aneuploidy associated with a positive screen in a South 
African population.  
3. Cost evaluation to determine the cost effectiveness of the screening programme. 
The findings in all women who had first trimester nuchal translucency screening will be 
reviewed.  The outcome at birth will be compared to the predicted condition. 
 
1.5 STUDY DESIGN 
This will be a descriptive study of the findings observed. 
 
 
 
 
 
 
 
 
 
 24 
 
2. MATERIALS AND METHODS 
2.1 STUDY SAMPLE-Study population, timing and sampling 
2.1.1 A retrospective analysis was performed on all records of patients who had first 
trimester nuchal translucency screening performed at the Chris Hani Baragwanath 
Hospital fetal medicine unit between July 2003 and July 2005. 
2.1.2 The study population comprised patients that had been attended to at the Chris Hani 
Baragwanath hospital antenatal clinic, and were then referred to the Fetal Medicine 
Unit for first trimester screening. 
2.1.3 The antenatal records of all patients who had received first trimester screening during 
the period under review were retrieved and reviewed.  There are no exclusion criteria. 
2.1.4 In order to determine the number of undiagnosed abnormalities in the group, all babies 
were examined by a paediatrician at birth to detect and describe dysmorphic features. 
In addition, babies attending the paediatric clinics were reviewed and assessed to 
determine the incidence of late presentation and sequelae. 
 
2.2 DATA COLLECTION 
The patients were identified by performing a computer search of the fetal medicine unit 
database for all women who had received first trimester screening between July 2003 and July 
2005.  
 
This database was provided by the Fetal Medicine Foundation. All of the names are stored in 
alphabetical order, but can be retrieved chronologically. The relevant hospital numbers of 
patients, who underwent first trimester screening in the CH Baragwanath complex, were 
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obtained. Anonymity of patients was maintained by use of a study number. A study number 
was assigned to each case. This number was then used to retrieve, review and record the 
following variables: maternal age, last normal menstrual period, previous chromosomal 
abnormality, ethnicity; ultrasound parameters included: fetal biometry, nuchal translucency 
measurement, abnormalities such as cranial defects, spinal defects, abdominal wall defects, 
and limb anomalies; results of fetal karyotype analysis and final outcome of pregnancy. 
 
In order to determine the number of undiagnosed abnormalities in the screen negative group, 
all the babies were examined at birth by a paediatrician to detect and describe dysmorphic 
features. In addition to this, the medical records of babies who subsequently attended the 
paediatric clinics, were reviewed and assessed to determine the incidence of late presentation 
and sequelae.  
Please refer to APPENDIX A. 
There were no exclusion criteria. 
 
2.3 THE MEASUREMENT OF NUCHAL TRANSLUCENCY 
2.3.1 EQUIPMENT 
The ultrasonographic scans were carried out on the Siemens G50 and the Medison Accuvix 
XQ machines, which provide high resolution ultrasonography. The ultrasonographic scans 
were performed trans-abdominally using a curvilinear 3.5MHz transducer or trans-vaginally 
using a 7 MHz transducer. 
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2.3.2 INTER-OBSERVER VARIABILITY 
The measurements of nuchal translucency were performed by 2 doctors who had received the 
Fetal Medicine Foundation certificate of competence in the theory and practice of the 10-14 
week scan.  
 
2.3.3 SONOGRAPHIC CRITERIA TO MAXIMIZE QUALITY OF 
NUCHAL TRANSLUCENCY SCREENING40 
The following fetal Medicine foundation Criteria were used to achieve uniformity of the 
results between these two doctors: 
a. Transabdominal or transvaginal approach should be left to the sonographer’s 
discretion, based on maternal body habitus, gestational age and fetal position. 
b. Gestation should be limited to between 10 to 14 weeks. 
c. Crown rump length should be limited to between 45 and 84 mm. 
d. The fetus should be examined in the midsagittal plane. 
e. The fetal neck should be in a neutral position. 
f. The magnification should be such that the fetus occupies at least three quarters of the image. 
Essentially the magnification should be increased to the extent that each increment in the 
distance between calipers should be only 0.1 mm. 
g. Care is taken to distinguish between fetal skin and amnion because, at this gestation, both 
structures appear as thin membranes. 
h. The maximum thickness of the subcutaneous translucency between the skin and the 
soft tissue overlying the cervical spine should be measured by placing the calipers on 
the lines as shown in Figure 2-1.  
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i. Calipers should be placed in an on to on position. (Figure 2-2)  
j. Calipers should be placed perpendicular to the fetal body axis. 
k. During the scan three measurements are taken and the maximum recorded. 
l. At least 20 minutes should be dedicated to the nuchal translucency measurement before 
abandoning the attempt as failed. 
 
FIGURE 2-1 MIDSAGITTAL SECTION OF FETUS AT APPROPRIATE MAGNIFICATION. 
Image kindly provided by Prof Ermos Nicolaou, University of the Witwatersrand. 
 
 
 
FIGURE 2-2 CORRECT POSITIONING OF CALIPERS.7 
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2.4 CALCULATION OF RISK 
The sonographic findings of the 10-14 week scan, as well as the demographic data, were then 
entered into the software programme provided by the Fetal Medicine Foundation and used to 
calculate the adjusted risk. A screen was considered to be positive if the adjusted risk was 
greater than 1:300 and negative if the risk was <1:300. 
 
2.5 EVALUATION OF THE COST OF SCREENING 
 In order to estimate cost the South African national health reference price list was used. The 
unit price of each process was taken into account.  
 
TABLE 2.1 NATIONAL HEALTH REFERENCE PRICE LIST 
Service Provided Cost  (Rands.cents) 
Cell culture (amniotic cells) 321.50 
Cell culture (chorionic villi) 429.00 
Cytogenetic analysis 1756.20 
Total cost of a first trimester screen 2359.70 
Total cost of a second trimester screen 2426.70 
 
 
2.6 ANALYSIS OF RESULTS 
 The results will be analyzed using Epi-Info 6.04 software and the p value will be set at <0.05 
to determine statistical significance. All patients’ in whom the outcome of the pregnancy was 
not available, were be excluded from sub analyses. For normally distributed data, the Analysis 
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of Variance (ANOVA) was used and the mean and standard deviation were recorded. The 
Kruskal Wallis test was used for non parametric data and the median and range were recorded. 
The study was commenced after Ethics approval was obtained. Protocol number: M041108. 
(Appendix B) 
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3. RESULTS 
A total of 428 patients had first trimester screening during this period. Thirteen patients (3%) 
were lost to follow up and were excluded from sub-analysis. 
 
3.1 FIRST TRIMESTER SCREENING OUTCOMES 
Of the 415 cases that were analyzed, 59 patients screened positive and 356 screened negative. 
Black patients comprised 77.6% of the total, with 14% Colored, 6% White and 2.1% Indian.  
 
3.2 FIRST TRIMESTER SCREENING CHARACTERISTICS 
Twenty six percent of women were older than 35 years. The results in Table 3.1 show that 
there is no significant difference between the mean ages of women who screened positive and 
those who screened negative. 
 
The first trimester screening characteristics of fetuses (Table 3.1) indicates that the crown 
rump length measurements of fetuses of women who had screened positive, were significantly 
shorter than fetuses of women in whom a negative screen result was obtained. The latter 
finding may have been due to possible early onset of intra-uterine growth restriction. 
Only 46% of women in the screen negative group and 23% of women in the screen positive 
group could recall their last normal menstrual period. 
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TABLE 3.1 FIRST TRIMESTER SCREENING CHARACTERISTICS 
Screen Negative Screen Positive Variable 
n=356 Range n=59 Range 
P-value 
Age of patient (yrs) 30.1 12-49 31 23-43 0.466 
Gestational age (weeks.days) 13.2 11.1-14.0 12.5 11.2-13.6 <0.01 
Crown Rump length (mm) 69.4 65-84 64.7 47.0-83.2 0.01 
Fetal Heart Rate (b/min) 164 146-180 170 147-185 0.34 
Nuchal Translucency 1.8 1.0-2.5 3.65 1.7-9.6 <0.01 
 
 
3.3 CHORIONIC VILLUS SAMPLING 
Table 3.2 summarizes the outcomes of screened patients in whom chorionic villus sampling 
was performed and those who elected not to have the procedure. Of the 59 patients who 
screened positive, 24 elected to have chorionic villus sampling (CVS)   This resulted in the 
detection of 5 chromosomal abnormalities (2 Trisomy 21; 1 Trisomy13; 1 Trisomy 18; 1 
Turner’s syndrome), 1 single gene defect (Tay-Sach’s disease). 
 
TABLE 3.2 SUMMARY OF FINDINGS OF CHORIONIC VILLUS SAMPLING 
Chorionic Villus Sampling Outcome 
Results 
Outcome 
of 
Screening 
Total  
screened 
n=428 Unsampled Sampled Normal Abnormal 
*Total 
Abnormal TOP IUFD Alive 
Positive 59 35 24 18 6 13 12 6 41 
Negative 356 347 9 8 1 1 1 6 346** 
TOP=Termination of pregnancy. 
 IUFD=Intrauterine fetal death. 
*Total abnormal= total number of chromosomally and phenotypically abnormal babies born. 
**The deficit of 3 babies was due to 1 postprocedural (CVS) loss and 2 stillbirths related to maternal conditions. 
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In addition to the CVS, the anatomical survey detected 2 fetuses with acrania, 2 multi-
structural abnormalities, and 4 fetuses had multi-structural abnormalities that were 
characteristic of Trisomy 13, Trisomy 18, Trisomy 21 and Turner’s syndrome respectively. 
The patient in whom a Trisomy 21 fetus was suspected, elected not to have a CVS, and 
decided to continue with the pregnancy. The remaining 12 patients, in whom abnormalities 
were detected, elected to have terminations of their pregnancy. There were 6 intrauterine fetal 
deaths in the remaining 46 patients who had screened positive. Five were due to pre-eclampsia 
and 1 was related to warfarin induced hydrocephalus.  
 
Of the 356 patients who screened negative, 2 patients had an increase in the adjusted risk 
when the risk was compared to the background risk. Both of these patients were offered a 
CVS. One elected to have a CVS and a Trisomy 18 fetus was diagnosed. This patient elected 
to have a termination of pregnancy. The remaining patient gave birth to a baby with no 
phenotypic abnormalities. The reasons for a CVS in the remaining 8 patients included: a 
previously abnormal fetus, advanced maternal age, a history of recurrent miscarriages, and in 
one case, confirmation of paternity. The karyotype of all these fetuses was normal. In this 
group, there was one post-procedural pregnancy loss. The 6 intrauterine fetal deaths were 
related to maternal complications such as eclampsia, abruptio placentae and over-
warfainization. The 2 fresh still births were largely due to maternal hypertensive 
complications that necessitated preterm delivery. 
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3.3.1 GENDER DISTRIBUTION DERIVED FROM FETAL KARYOTYPE 
RESULTS 
Table 3.3 illustrates that male fetuses had a significantly higher false positive screen as well as 
a higher frequency of chromosomal or structural abnormalities. 
 
TABLE 3.3 GENDER DISTRIBUTIONS DERIVED FROM KARYOTYPE RESULTS  
Outcome  Male % Female % p-value 
Normal  n=20 70 30 <0.01 
Abnormal n=14 64.3 35.7 <0.01 
 
3.4 STRUCTURAL ABNORMALITIES DETECTED 
Table 3.4 summarizes the abnormalities which resulted in a positive screen, together with 
those which were confirmed using CVS. One patient, in whom a Trisomy 21 fetus was 
diagnosed, was not able to accept the diagnosis of Trisomy 21, even after delivery of the baby. 
One patient in whom the anatomical survey suggested Trisomy 13 and one in whom Turner’s 
syndrome was suspected, elected to have terminations of their pregnancies.  The abnormal 
karyotype of these fetuses were confirmed after delivery. The patients in whom fetuses with 
multi-structural abnormalities were detected, as well as the patients with fetuses that had 
acrania, chose to terminate their respective pregnancies. After delivery, the karyotype of these 
fetuses were found to be normal. 
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TABLE 3.4 STRUCTURAL ABNORMALITIES DETECTED 
Abnormality detected First  
Trimester 
Screen 
Chorionic Villus 
Sampling 
Trisomy 21 3 2 
Trisomy 13 2 1 
Trisomy 18 2 2 
Turner’s Syndrome 2 1 
Tay-Sach’s Disease 1 1 
Multi-Structural Abnormality 2  
Acrania 2  
 
3.5 TWIN PREGNANCIES 
Of the 5 twin pregnancies that underwent first trimester nuchal translucency screening, none 
were found to have fetuses with aneuploidy. (Table 3.5)  
 
TABLE 3.5 RESULTS OF FIRST TRIMESTER SCREENING IN TWIN 
PREGNANCIES 
Means Dichorionic n=5 Monochorionic n=4 P-value 
Nuchal Translucency (mm) 1.4 (1.3-1.6) 2.1 (2.0-2.3) <0.01 
Maternal age (years) 25 26 0.45 
 
Monochorionic twin pregnancies had a higher mean nuchal translucency measurement than 
dichorionic twin pregnancies, and this may have been related to an early onset of twin-to-twin 
transfusion syndrome. 
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3.6 EVALUATION OF THE FIRST TRIMESTER SCREENING 
PROGRAMME 
Table 3.6 confirms that the first trimester screening programme was effective in terms of 
achieving a high sensitivity, specificity and positive predictive value.  
 
TABLE 3.6 EVALUATION OF THE FIRST TRIMESTER SCREENING 
PROGRAMME 
First Trimester Screening % 95 % CI 
Sensitivity 92.9 64.2-99.6 
Specificity 88.6 84.9-91.4 
Positive Predictive Value 22.2 12.7-35.1 
Negative Predictive Value 99.7 98.2-100 
False Positive Rate 11 8.9-15.4 
Overall* 7.9 5.6-11.0 CVS Uptake Rate 
High Risk** 5.7 28.0-54.2 
* Overall CVS uptake (Includes all patients who had a CVS) 
†High Risk CVS uptake rate (Includes only patients who had a positive screen and elected to have a CVS performed) 
 
 
3.7 EVALUATION OF COST EFFECTIVENESS  
Table 3.7 compares the actual cost of the first trimester screening programme at the Chris 
Hani Baragwanath hospital (indicated by blue background)  to the hypothetical cost of a 
second trimester screening programme in the same group of patients (indicated by a yellow 
background). 
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TABLE 3.7 COST EFFECTIVENESS OF THE CHRIS HANI BARAGANATH 
HOSPITAL SCREENING PROGRAMME 
Invasive  
Procedure  
Uptake 
Screening 
programme  
n Percentage 
Trisomy 21 
Detected 
Procedure  
Offered 
% No 
Cost in 
Rands 
MA > 35 years  108 50 Amniocentesis 26 108 R 262 083.60 
aMA +NT+NB 59 100 CVS 7.9 33 R 77 870.10 
bMA+NT+NB 59 100 CVS 5.7 24 R 56 632.80 
MA=Maternal age 
NT=Nuchal translucency screening 
NB=Nasal bone screening 
CVS=Chorionic villus sampling 
%=Percentage 
No=Number of patients  
*=Cost evaluation of all patients who elected to have chorionic villus sampling 
†=Cost evaluation which only incorporates high risk patients (adjusted risk of ≥ 1:300) who elected to have chorionic villus 
sampling 
 
If amniocentesis were performed in all 108 patients in the second trimester, only 50% of the 
fetuses with Trisomy 21 would have been detected.  The remaining 50% would have occurred 
in those aged less than 35 years. The actual cost of the first trimester screening programme 
amounted to 29% of the cost that would have been incurred by a second trimester screening 
programme, and 100% of Trisomy 21 fetuses were diagnosed.  
 
If strict protocols were implemented and CVS was performed in only high risk patient with a 
risk cut off of 1:300 or more, then the cost incurred would have been only 21% of that which 
would have applied to a second trimester screening programme. 
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4. DISCUSSION 
During this study period, there were a total of 428 women who received first trimester 
screening. The racial distribution was normal for a South African population.  
 
4.1 SCREENING CHARACTERISTICS 
4.1.1 MATERNAL AGE 
The a priori risk determined by a maternal age of greater than 34 years, was previously the 
sole criterion used to delineate women who were at high risk of having a fetus with a 
congenital abnormality, especially Trisomy 21. It does stand to reason that a women’s risk of 
having an abnormal fetus should not be substantially increased when she is 35 years old in 
comparison to her risk on the eve of her 35th birthday. The fact that there is no statistical 
difference between the mean ages of women who screened positive and women, who screened 
negative (Table 3.1), substantiates this. Hence, whilst maternal age is an important factor in 
determining the a priori risk, it is no longer the sole criterion for screening and all women 
should receive first trimester screening if possible. 
 
4.1.2 GESTATIONAL AGE 
Nuchal translucency varies with gestational age and no single cut-off value can be used to 
predict aneuploidy, as has already been pointed out. Accordingly, the precise ascertainment of 
gestational age is important to achieve an accurate nuchal translucency screen. In this study it 
became apparent that the majority of women were not accurate in their recall of their last 
normal menstrual period. A first trimester ultrasound examination would thus also promote 
accurate dating of the pregnancy.  
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4.1.3 NUCHAL TRANSLUCENCY AND CROWN RUMP LENGTH 
The NT measurement usually increases with gestational age.45 In this study, fetuses that 
screened positive were more likely to have a nuchal translucency in excess of 2.5mm and were 
significantly shorter in length than fetuses that screened negative, possibly due to an early 
onset of intra-uterine growth restriction. In women who cannot recall their last menstrual 
period correctly, the benefit of early sonographic dating may be negated if there is early onset 
intra-uterine growth restriction.  
 
4.2 CHORIONIC VILLUS SAMPLING 
Of the 59 patients who screened positive, 24 elected to have chorionic villus sampling, and 5 
chromosomal abnormalities were detected (2 Trisomy 21, 1 Trisomy13, 2 Trisomy18, 1 
Turners syndrome), and 1 single gene defect (Tay-Sach’s disease). The patient in whom a 
fetus with Tay-Sach’s disease was diagnosed, had screened positive with a nuchal 
translucency measurement of 2.8 mm, and although there is no current literature to support the 
diagnosis of a single gene defect by means of assessment of nuchal translucency, the positive 
screen may have been related to the genetic defect. 
 
Of the 356 patients who screened negative, 2 had an increase in their adjusted risk when it was 
compared to their a priori risk. When these women received counseling, it was communicated 
to them that their risk of having a congenitally abnormal fetus was higher than their a priori 
risk had suggested and one of them elected to have chorionic villus sampling when offered. A 
diagnosis of Trisomy18 was made in that fetus.  
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The other patient chose to forgo invasive procedural diagnosis in favor of a 20 week follow-up 
sonographic evaluation and there were no structural abnormalities, nor sonographic markers of 
aneuploidy, detected. 
 
Whilst the cut of limit for chorionic villus sampling has been set at 1:3001, it is difficult, when 
counseling a patient, to reassure the patient that the adjusted risk, though increased is 
“acceptable”.   
 
Respect for autonomy is a central principle in ethics and in law46.  It is not uncommon for 
women to decline an invasive procedure even if the risk of aneuploidy is higher after a first 
trimester screen, and this decision must be respected. By the same token, some women find 
even a minimal increase in the adjusted risk unacceptable. Hence, the above-mentioned patient 
with a negative screen but an increase in the adjusted risk opted to have invasive testing 
performed. Implementation of this principle, led to the detection of one fetal aneuploidy in the 
group who screened negative, but had an increase in the adjusted risk. An increase in the 
adjusted risk may be as important as a positive screen of 1:300. 
 
The fetus which falsely screened negative had a karyotype of Trisomy 18, and it is possible 
that the false negative result was related to the specific abnormality.  There have been several 
reports where it was observed that fetuses with a Trisomy 18 karyotype displayed an early 
resolution of increased nuchal translucency.47,48 Celentano, et al47, described an increased 
nuchal translucency of 2.3mm at 12 weeks gestation, which had resolved to 1.6mm at 14 
weeks gestation. The same phenomenon, of early resolution of an increased nuchal 
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translucency, has been described in Trisomy 13.48 To address this problem, Celentano, et al47 
reinforced the importance of first trimester biochemical screening. 
 
4.2.1 INVASIVE PROCEDURE LOSS RATE 
One patient, who had screened negative, but had elected to have chorionic villus sampling for 
the purpose of paternity testing, had a miscarriage within 24 hours of the procedure. This was 
the only pregnancy loss attributable to the procedure which occurred in the study. Loss rates, 
exclusively due to chorionic villus sampling, have been quoted to be between 7.6% and 14 %.7 
 
4.2.2 GENDER DISTRIBUTION 
Male fetuses were observed to have a greater frequency of false positive screens and male 
fetuses were more likely to screen positive. This finding suggests that male fetuses may have a 
larger nuchal translucency measurement than female fetuses. There is no supporting data for 
these findings and this most certainly merits further investigation. (Table 3.3) 
  
4.3 STRUCTURAL ABNORMALITIES DETECTED 
Only one of the three Trisomy 21 fetuses had a structural abnormality detected on anatomical 
survey. This fetus had the characteristic ‘lemon sign’ which has frequently been described.7 
The mother of this fetus declined invasive procedural diagnosis, and the presence of the 
abnormality was confirmed after delivery.    
 
The two fetuses with suspected Trisomy 13 had multiple structural abnormalities. One had 
holoprosencephaly, cyclopia, an increased nuchal translucency and an exomphalos. On the 
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grounds of these findings the mother requested a termination of pregnancy and the karyotype 
was confirmed to be normal after delivery. The other fetus had only an exomphalos and the 
post CVS karyotype revealed Trisomy of chromosome 13. 
 
Of the two fetuses with multi-structural defects, the one had gastroschisis; renal agenesis and 
bilateral clubbed feet and the other had kyphoscoliosis, an exomphalos, polydactyly, and 
bilateral clubbed feet. In view of the severity of the abnormalities, the parents of both fetuses 
elected to terminate the pregnancies and both the karyotypes were found to be normal post 
termination.  
 
As observed in Table 3.4, first trimester screening has proven to be valuable in the diagnosis 
of multi-structural. 
 
4.4 FIRST TRIMESTER SCREENING IN TWIN PREGNANCIES 
Table 3.5 demonstrated no significant difference between the mean ages of women with 
dichorionic twin pregnancies when compared to those with monochorionic twin pregnancies. 
There were no aneuploid fetuses among the twin pregnancies.  The mean nuchal translucency 
was significantly higher in monochorionic twins. This data is similar to the findings in 
previous studies.9 Sebire, et al49 reported a 1.5 times greater nuchal translucency in 
monochorionic twins compared with dichorionic twins.  
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4.5 EVALUATION OF FIRST TRIMESTER SCREENING PROGRAM 
The Chris Hani Baragwanath hospital first trimester screening programme to detect structural 
and chromosomal abnormalities was found to have a sensitivity of 92.9% and a specificity of 
88.6%. The screening programme therefore has a high positive and negative predictive value.  
 
These results compare favorably with the findings of Snijders, et al1, where they achieved a 
sensitivity of 82% for a false positive rate of 8.3% when first trimester screening for Trisomy 
21 was implemented without biochemical screening. The high false positive rate noted in the 
Chris Hani Baragwanath Hospital screening programme can probably be attributed to the fact 
that a population at high risk was selected for screening.  
 
Although this first trimester screening programme is meant to target the general population, 
patients attending the Chris Hani Baragwanath Hospital are usually referred for antenatal care 
due to previous poor outcomes and complications experienced in the index pregnancy. This 
lowered the threshold for invasive testing and the high false positive rate can possibly be 
attributed to this. 
 
The overall Chorionic villus sampling uptake rate was high because strict criteria for offering 
the test were not adhered to. However, the Chorionic villus sampling rate of women who 
actually required the test (women with a risk of 1:300 or more) was 5.7%, which is also in 
keeping with the findings of Snijders, et al.1 The data obtained reflects that the service offered 
to patients at the Chris Hani Baragwanath Hospital is effective and is comparable with 
international standards. 
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 With the ever increasing prevalence of human immunodeficiency virus seropositivity among 
patients, it is of utmost importance to limit the invasive procedure rate. The employment of 
first trimester nuchal translucency screening, as opposed to second trimester screening 
followed by amniocentesis, is one way of achieving such limitation. 
Furthermore the first trimester nuchal translucency screening programme at the Chris Hani 
Baragwanath Hospital has been found to be of value in screening for structural as well as 
chromosomal abnormalities in a South African population. 
 
4.6 COST EFFECTIVENESS OF THE CHRIS HANI BARAGWANATH 
HOSPITAL FIRST TRIMESTER SCREENING PROGRAM 
Table 3.7 demonstrates that the first trimester screening programme for Trisomy 21 is cost 
effective in terms of the percentage of Trisomy 21 diagnosed versus the cost which would 
have been incurred when compared to a second trimester screening programme. 
 
It would be difficult to use the data obtained from this study to evaluate the cost effectiveness 
with respect to the diagnosis of abnormalities other than Trisomy 21, as there is no data to 
support the comparison of screen positives and negatives in the first and second trimesters. 
 
In a country like South Africa were budget limitations dictate the quality of medical services 
provided, the first trimester screening programme has, in this study, been shown to be cost 
effect with an internationally equivalent efficacy. 
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4.7 CONCLUSION 
This retrospective descriptive analysis of nuchal translucency as a method of first trimester 
screening for abnormalities has revealed interesting results.  
 
The population screened reflected a South African racial distribution. Only 26% of women 
were of advanced maternal age and only 1 had a fetus with Trisomy 21. There was no 
significant difference between the mean ages of women whose fetuses screened positive and 
those who screened negative. 
 
Fetuses which screened positive had a smaller crown rump length than those who screened 
negative, and this could possibly be attributed to an early onset of intra-uterine growth 
restriction. 
 
Chorionic villus sampling results suggest that an increase in the adjusted risk is as important 
as a screen positive result. The incidental diagnosis of Tay-Sach’s disease, though 
unsubstantiated by a literature review, suggests that this single gene defect may be amenable 
to early detection by the implementation of first trimester nuchal translucency screening. This 
would require further investigation in the future. Sub-analysis of gender predisposition 
suggests that male fetuses have a higher tendency to be affected as well as to falsely screen 
positive. This finding also requires further investigation in a study with a greater power. 
 
The first trimester screening programme is beneficial in the diagnosis of both structural 
abnormalities and chromosomal abnormalities, especially the Trisomies. More importantly 
 45 
 
this screening programme has a sensitivity of 92.9% at an overall invasive procedure uptake 
rate of 7.9% which is comparable to international data. The high false positive rate of 11% 
may be attributed to the screening programme being implemented to a high risk population at 
a tertiary care institution. 
 
The benefit of a reduced procedure rate in the setting of a high seropositivity of the Human 
Immunodeficiency Virus would support the implementation of a first trimester screening 
programme. 
 
The Chris Hani Baragwanath Screening programme has addressed the ever present cost factor 
and provides effective screening at a third of the cost that would have been incurred if the 
same patients were screened in the second trimester.  The cost and benefit in terms of man-
hours required to implement the programme in the general population remains to be assessed. 
 
In order to ensure sustainability and development of this programme, more doctors need to 
receive the appropriate training and accreditation to perform first trimester nuchal 
translucency screening. In addition, the public needs to be made aware that such a test exists 
and more screening centers need to be made available to the public. The bottom line is 
additional funding. 
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